Compare Charles River Laboratories Intl. Inc (CRL) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.24 (market cap $11.14B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.94. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SJNK | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $25.63 |
52-Week Low | $145.57 | $24.75 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SJNK trades at $24.88, down slightly by 0.12% over the past day. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF continues its regular dividend payments, with recent distributions of $0.14 and $0.15 per share. Recent news highlights mixed sentiment, with some analysts cautioning on high-yield bonds while institutional positions see increases.
The outlook for SJNK is clouded by bearish technicals and cautious analyst sentiment, though steady dividends provide income support. Key risks include interest rate sensitivity and credit spread volatility in the high-yield bond market. Investors should weigh the income generation against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
